Carcinoid Tumors
October 2020 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view.
Authors:Spada F, Pellicori S, Zampino G, Funicelli L, Gervaso L, Laffi A, Rubino M, Garcia-Carbonero R, Fazio N
Institution:Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Journal:Endocrine. 2020 Oct;70(1):6-10. doi: 10.1007/s12020-020-02419-w. Epub 2020 Jul 17.

2:The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases.
Authors:Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A
Institution:Tumor Immunology Lab, Department of Pathology, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway.
Journal:Scand J Immunol. 2020 Aug;92(2):e12893. doi: 10.1111/sji.12893. Epub 2020 Jun 9.

3:Diagnostic imaging of typical lung carcinoids: relationship between MDCT, (111)In-Octreoscan and (18)F-FDG-PET imaging features with Ki-67 index.
Authors:Danti G, Berti V, Abenavoli E, Briganti V, Linguanti F, Mungai F, Pradella S, Miele V
Institution:Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy.
Journal:Radiol Med. 2020 Aug;125(8):715-729. doi: 10.1007/s11547-020-01172-4. Epub 2020 Mar 18.

4:Bronchial Sleeve Resection and Double-Barreled Reconstruction for a Carcinoid Tumor.
Authors:Fukutomi T, Yoshizu A, Matsuda K, Okamoto H
Institution:Department of Thoracic Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. Electronic address: Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Journal:Ann Thorac Surg. 2020 Jul;110(1):e67-e69. doi: 10.1016/j.athoracsur.2020.01.032. Epub 2020 Feb 28.

5:CSTI-300 (SMP-100); a Novel 5-HT(3) Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome.
Authors:Roberts A, Grafton G, Powell AD, Brock K, Chen C, Xie D, Huang J, Liu S, Cooper AJ, Brady CA, Qureshi O, Stamataki Z, Manning DD, Moore NA, Sargent BJ, Guzzo PR, Barnes NM
Institution:Neuropharmacology Research Group, Institute of Clinical Sciences (A.R., G.G., A.J.C., C.A.B., O.Q., N.M.B.) and Institute of Immunology and Immunotherapy (Z.S.), College of Medical and Dental Sciences
Journal:J Pharmacol Exp Ther. 2020 Apr;373(1):122-134. doi: 10.1124/jpet.119.261008. Epub 2020 Feb 26.

6:Is it possible to discriminate pulmonary carcinoids from hamartomas based on CT features?
Authors:Coruh AG, Kul M, Kuru Öz D, Yenigün B, Cansız Ersöz C, Özalp Ateş F, Atasoy Ç
Institution:Department of Radiology, School of Medicine, Ankara University, Talatpa?a Bulvar?, S?hhiye, 06100 Ankara, Turkey. Electronic address: Department of Radiology, School of Medicine, Koc University, ?stanbul, Turkey.
Journal:Clin Imaging. 2020 Jun;62:49-56. doi: 10.1016/j.clinimag.2020.02.001. Epub 2020 Feb 8.

7:Primary malignant ovarian carcinoid; management and outcomes.
Authors:Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K
Institution:Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA. Electronic address: Division of Gynecologic Oncology, Weill Cornell Medicine, New York, NY, USA.
Journal:Gynecol Oncol. 2020 Apr;157(1):101-105. doi: 10.1016/j.ygyno.2020.01.002. Epub 2020 Jan 17.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount

Medifocus Guidebook on Carcinoid Tumors

Updated: January 6, 2021
162 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: April 5, 2021

What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
Newcastle, England

"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
Nanaimo, British Columbia

"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
Agoura Hills, California

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2021 Medifocus, Inc. All rights reserved.